Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Piessen, Guillaume ^a,b,c   Messager, Mathieu ^a,b,c   Le Malicot, Karine ^d   Robb, William B ^a,b   Di Fiore, Frédéric ^e   Guilbert, Marie ^a,b   Moreau, Marie ^d   Christophe, Véronique ^b   Adenis, Antoine ^f   Mariette, Christophe ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d Fédération Francophone de Cancérologie Digestive   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Couple; Emotion; Gastric adenocarcinoma; Perioperative chemotherapy; Randomized study; Signet ring cells; Surgery

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLAVIEN DINDO SEVERITY INDEX; COGNITION; DISEASE FREE SURVIVAL; EMOTION; HISTOPATHOLOGY; HUMAN; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA; SURGICAL MORTALITY; ABDOMINAL SURGERY; ADJUVANT CHEMOTHERAPY; CARCINOMA, SIGNET RING CELL; CLINICAL TRIAL; CONTROLLED STUDY; METHODOLOGY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMACH NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SIGNET RING CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DIGESTIVE SYSTEM SURGICAL PROCEDURES; EPIRUBICIN; FLUOROURACIL; HUMANS; RESEARCH DESIGN; STOMACH NEOPLASMS;

EID: 84879563734     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-281     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999, 49:33-64.
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and socalledintestinal-type. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
4. Fenoglio-Preiser C, Muñoz N, Carneiro F, Powell SM, Correa P, Rugge M, Guilford P, Sasako M, Lambert M, Stolte M. Gastric carcinoma. Pathology and Genetics of Tumours of the Digestive System of Tumors 2000, 35-50. Lyon: IARCC press, Hamilton SR, Aaltonen LA.
5. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev 2009, 18:1945-1952.
6. Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in th United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med 2004, 128:765-770.
7. Baiocchi GL, Tiberio GA, Minicozzi AM, Morgagni P, Marrelli D, Bruno L, Rosa F, Marchet A, Coniglio A, Saragoni L, Veltri M, Pacelli F, Roviello F, Nitti D, Giulini SM, De Manzoni G. Multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg 2010, 252:70-73.
8. Messager M, Lefevre J, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The Impact of Perioperative Chemotherapy on Survival in Patients With Gastric Signet Ring Cell Adenocarcinoma: A Multicenter Comparative Study. Ann Surg 2011, 254:684-693.
9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
10. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29:1715-1721.
11. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefgih S, Oliveira J, Bognel C, Lasser P, Ychou, Elias D. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994, 30A:1263-1269.
12. Piessen G, Messager M, Leteurtre E, Triboulet JP, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009, 250:878-887.
13. Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep 2000, 7:841-846.
14. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemo sensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008, 14:2012-2018.
15. Piessen G, Amielh D, Messager M, Vinatier E, Leteurtre E, Triboulet JP, Mariette C. Is pre-treatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma?. World J Surg 2012, 36:346-354.
16. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004, 240:205-213.
17. Hermanek P. pTNM and residual tumor classifications: problems of assessment and prognostic significance. World J Surg 1995, 19:184.
18. Slim K, Blay JY, Brouquet A, Chatelain D, Comy M, Delpero JR, Denet C, Elias D, Fléjou JF, Fourquier P, Fuks D, Glehen O, Karoui M, Kohneh-Shahri N, Lesurtel M, Mariette C, Mauvais F, Nicolet J, Perniceni T, Piessen G, Regimbeau JM, Rouanet P, sauvanet A, Schmitt G, Vons C, Lasser P, Belghiti J, Berdah S, Champault G, Chiche L, Chipponi J, Chollet P, De Baère T, Déchelotte P, Garcier JM, Gayet B, Gouillat C, Kianmanesh R, Laurent C, Meyer C, Millat B, Msika S, Nordlinger B, Paraf F, Partensky C, Peschaud F, Pocard M, Sastre B, Scoazec JY, Scotté M, Triboulet JP, Trillaud H, Valleur P. Digestive oncology: surgical practices. J Chir (Paris) 2009, 146:S11-S80.
19. Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Société Française de Chirurgie Digestive. Perioperative care in digestive surgery. J Chir (Paris) 2005, 142:14-28.
20. Smith BR, Stabile BE. Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg 2009, 144:506-510.